A wealth of recent evidence implicates increasing obesity levels in the rising global epidemic of type 2 diabetes. At a cellular level, high fatty acid concentrations contribute to increasing β-cell dysfunction and eventual β-cell failure. We have shown that the thiazolidinedione (TZD) rosiglitazone has direct effects on pancreatic β-cell function. The aim of this study was to determine the cell signalling molecules mediating these effects, and to test the hypothesis that rosiglitazone can protect pancreatic β-cells from the detrimental effects of free fatty acids.
|Date of Award||Sep 2011|